search
Back to results

Pain Management Support Study for Cancer Survivors

Primary Purpose

Pain, Chronic, Opioid Use

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Interactive Music Therapy
Verbal-based support
Sponsored by
Drexel University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pain, Chronic focused on measuring music therapy, pain management, opioid use, cancer survivors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult cancer survivors
  • chronic pain for ≥ 3 months
  • chronic opioid use (i.e., use of opioids for more than 90 days)
  • willingness to reduce the amount of opioids currently taking

Exclusion Criteria:

  • history of polysubstance abuse/substance use disorder
  • currently receiving methadone maintenance or suboxone treatment
  • active psychosis or dementia
  • inability to speak or write English
  • moderate to severe hearing impairment

Sites / Locations

  • Hahnemann University Hospital
  • Thomas Jefferson Sidney Kimmel Cancer Center
  • Cancer Treatment Centers of America (CTCA)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Interactive Music Therapy

Verbal-based Support

Arm Description

Ten 45-minute individual interactive music therapy sessions.

Ten 45-minute individual verbal support sessions.

Outcomes

Primary Outcome Measures

Daily opioid dose
Taking information from the Prescription Drug Monitoring Program, we will calculate the mean daily opioid dose for each participant by dividing the quantity of opioid pills prescribed by the number of days for which it was supplied.
Self-reported opioid use
Self-report on intake of opioids and NSAIDS through daily pain medication log

Secondary Outcome Measures

Pain intensity
Measured by PROMIS® Pain Intensity-Short Form (SF)3a
Pain interference
Measured by PROMIS® Cancer-Pain Interference -SF 6b
Self-efficacy
Measured by PROMIS® Self-Efficacy of Symptoms
Patient perception of change
Measured by Patient Global Impression of Change Scale (PGIC)
Physician perception of change
A brief questionnaire asking about their perception of how the participant is doing in terms of pain management
Anxiety
Measured by the PROMIS® Emotional Distress-Anxiety - SF6a
Depression
Measured by the PROMIS® Depression - SF 6a
Sleep quality
Measured by the PROMIS® Sleep Disturbance - SF4a

Full Information

First Posted
December 17, 2018
Last Updated
February 18, 2022
Sponsor
Drexel University
search

1. Study Identification

Unique Protocol Identification Number
NCT03782506
Brief Title
Pain Management Support Study for Cancer Survivors
Official Title
The Impact of Music Therapy on Opioid Use in Cancer Survivors With Chronic Pain
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Drexel University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pain in cancer survivors is difficult to treat, and unrelieved pain can greatly reduce a person's quality of life. Opioids are often prescribed for pain management, yet they can have undesirable side effects and may put someone at risk for addiction or dependence. The purpose of this study is to examine the impact of an interactive music therapy intervention on pain management and opioid use in cancer survivors.
Detailed Description
As many as 40% of cancer survivors report experiencing chronic pain, and recent research indicates that pain is not well managed. Opioids are often prescribed during active cancer treatment for pain management, and many cancer survivors continue the same pain management regimen long after completing their cancer treatment. Reports indicate that prescription rates are up to 1.22 times higher for cancer cancer survivors than people without a cancer diagnosis, and the American Society of Clinical Oncology recommends that opioid tapering should be a priority once someone moves into survivorship status. Music interventions have been used for pain management in people with cancer, yet few studies have examined music therapy for chronic pain in cancer survivors. Moreover, none of these studies have not examined opioid use as a measure. Therefore, the overarching goals of this pilot study are to investigate the impact of an interactive music therapy (IMT) intervention on pain management and opioid use in cancer survivors with chronic pain versus a verbal-based support program (social attention control). This pilot study uses a mixed methods intervention design in which qualitative data (i.e. semi-structured follow-up interviews) are embedded within a randomized controlled trial. We will randomize 40 cancer survivors to one of two 10-session treatments: 1) Interactive Music Therapy or 2) Social Attention Control. Primary (mean daily opioid use) and secondary outcomes (pain intensity, pain interference, pain-related self-efficacy, patient perception of change, and physician perception of change in pain management) will be measured at baseline, post-intervention and 3-month follow-up. Follow-up interviews with a subsample of 12 participants and 4 physicians will enable us to gain a better understanding of potential treatment benefits, learn about challenges encountered, and obtain suggestions for treatment optimization. This is the first music therapy study to examine the benefits of music therapy for opioid tapering in cancer survivors with chronic pain and the results will be used to establish estimates of variance for sample size calculations for a larger-scale randomized control trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Chronic, Opioid Use
Keywords
music therapy, pain management, opioid use, cancer survivors

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Interactive Music Therapy
Arm Type
Experimental
Arm Description
Ten 45-minute individual interactive music therapy sessions.
Arm Title
Verbal-based Support
Arm Type
Active Comparator
Arm Description
Ten 45-minute individual verbal support sessions.
Intervention Type
Behavioral
Intervention Name(s)
Interactive Music Therapy
Intervention Description
Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
Intervention Type
Behavioral
Intervention Name(s)
Verbal-based support
Intervention Description
Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
Primary Outcome Measure Information:
Title
Daily opioid dose
Description
Taking information from the Prescription Drug Monitoring Program, we will calculate the mean daily opioid dose for each participant by dividing the quantity of opioid pills prescribed by the number of days for which it was supplied.
Time Frame
Through study completion, a maximum of 28 weeks
Title
Self-reported opioid use
Description
Self-report on intake of opioids and NSAIDS through daily pain medication log
Time Frame
Through study completion, a maximum of 28 weeks
Secondary Outcome Measure Information:
Title
Pain intensity
Description
Measured by PROMIS® Pain Intensity-Short Form (SF)3a
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Pain interference
Description
Measured by PROMIS® Cancer-Pain Interference -SF 6b
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Self-efficacy
Description
Measured by PROMIS® Self-Efficacy of Symptoms
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Patient perception of change
Description
Measured by Patient Global Impression of Change Scale (PGIC)
Time Frame
At post-intervention (week 10) and 3-month follow up
Title
Physician perception of change
Description
A brief questionnaire asking about their perception of how the participant is doing in terms of pain management
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Anxiety
Description
Measured by the PROMIS® Emotional Distress-Anxiety - SF6a
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Depression
Description
Measured by the PROMIS® Depression - SF 6a
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up
Title
Sleep quality
Description
Measured by the PROMIS® Sleep Disturbance - SF4a
Time Frame
At baseline, post-intervention (week 10), and 3-month follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult cancer survivors chronic pain for ≥ 3 months chronic opioid use (i.e., use of opioids for more than 90 days) willingness to reduce the amount of opioids currently taking Exclusion Criteria: history of polysubstance abuse/substance use disorder currently receiving methadone maintenance or suboxone treatment active psychosis or dementia inability to speak or write English moderate to severe hearing impairment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joke Bradt, PhD
Organizational Affiliation
Drexel University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hahnemann University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19102
Country
United States
Facility Name
Thomas Jefferson Sidney Kimmel Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Cancer Treatment Centers of America (CTCA)
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19124
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
We will make the de-identified datasets available to other researchers. Researchers will be asked to submit a formal request for data sharing to the PI that outlines the purpose of the secondary data analysis. Data and associated documentation will be made available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
IPD Sharing Time Frame
After completion of study report and publication of the results
IPD Sharing Access Criteria
We will make the de-identified datasets available to other researchers. Researchers will be asked to submit a formal request for data sharing to the PI that outlines the purpose of the secondary data analysis. Data and associated documentation will be made available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.

Learn more about this trial

Pain Management Support Study for Cancer Survivors

We'll reach out to this number within 24 hrs